|
|
|
|
JOURNAL
OF
SPORTS SCIENCE &
MEDICINE
|
 |
|
Research
article
|
INFLUENCE OF INTRAMUSCULAR APPLICATION OF AUTOLOGOUS CONDITIONED PLASMA ON SYSTEMIC CIRCULATING IGF-1 |
|||||||||
Gert Schippinger1,2  ,
Karl Oettl3, Florian Fankhauser2, Stefan Spirk1,4,
Wolfgang Domej5 and Peter Hofmann1,4 |
|||||||||
1Human Performance Research Graz, University of Graz and Medical University of Graz, 2Sportchirurgie Plus Graz, 3Institute of Physiological Chemistry, Medical University of Graz, 4Institute of Sports Science, University of Graz, 5Department of Internal Medicine, Medical University of Graz, Austria |
|||||||||
|
|||||||||
© Journal of Sports Science and Medicine (2011) 10, 439 - 444 |
|||||||||
|
|
| ABSTRACT | |||
| Platelet-rich plasma (PRP) to increase levels of platelets and
growth factors has been used for the treatment of sports injuries suggesting
to improve healing and regeneration. This method offers some potential especially
for elite athletes. However, the insulin like growth factor-1 (IGF-1) is
prohibited by the World Anti Doping Agency and, in addition, there may be
a possible link between increased levels of IGF-1 and cancer risk. Aim of
the study was to evaluate a systemic increase of IGF-1 after local intramuscular
administration of PRP in young healthy moderately trained male subjects.
Blood samples were drawn and PRP preparation was performed by means of centrifugation.
Enriched plasma was injected into the gluteus muscle. Venous blood was collected
and serum prepared before as well as after 0.5, 3 and 24 hours after PRP
administration. IGF-1 analysis was performed applying an ELISA test kit.
No significant systemic increase of mean IGF-1 was found after the PRP injection.
Only one subject showed an increase after 24 h, but all IGF-1 values were
found within reference limits. We conclude that a single intramuscular application
of PRP does not significantly increase systemic IGF-1 levels. Therefore,
a single application of PRP is safe with respect to systemic IGF-1 response
and cancer risk and this should be allowed for treatment of muscle injuries
in elite athletes.
Key words: Platelet rich plasma, intramuscular application, IGF-1, cancer risk, doping. |
|